Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥443.9bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥228.6bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥66.5bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥36.8bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥66.4bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥36.6bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.75Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.66Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.26Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.26Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥53.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥36.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥30.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥67.272023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.992023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥67.242023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.972023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥119m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥84.1bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥10.6bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥265.7bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥57.6bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥94.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥8.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥443.8bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥76.6bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 690
ItemContextValueUnit
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember2000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember-14199000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-10801000000JPY
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-2877000000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-27876000000JPY
Total transactions with owners IFRSPrior1YTDDuration-27876000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember38716000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember51923000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-20428000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember876498000000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember224395000000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember1171105000000JPY
Equity IFRSPrior1QuarterInstant1171105000000JPY
Equity IFRSPrior1YearInstant_ShareCapitalIFRSMember38716000000JPY
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember51759000000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-11539000000JPY
Equity IFRSPrior1YearInstant_RetainedEarningsIFRSMember874272000000JPY
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember157855000000JPY
Equity IFRSPrior1YearInstant_EquityAttributableToOwnersOfParentIFRSMember1111063000000JPY
Equity IFRSPrior1YearInstant1111063000000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember50092000000JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember50092000000JPY
Profit loss IFRSCurrentYTDDuration50092000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember115310000000JPY
Other comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember115310000000JPY
Other comprehensive income IFRSCurrentYTDDuration115310000000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember50092000000JPY
Comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember115310000000JPY
Comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember165402000000JPY
Comprehensive income IFRSCurrentYTDDuration165402000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-2000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-2000000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration-2000000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass